Clinical Trial Update: HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of selinexor in combination with a bispecific antibody (HCMT/MM2401) for relapsed/refractory multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• HCMT/MM2401
• XPOVIO (selinexor) (selinexor)

Snippet

Sponsor: Duke University | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Phase 2 | Status: RECRUITING